Announcements
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Announces Participation in the RBCCM Global Healthcare Conference
- ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
More ▼
Key statistics
As of last trade Resmed Inc (0KW4:LSE) traded at 212.01, -6.68% below its 52-week high of 227.19, set on Jul 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 212.40 |
Average volume | 181.33 |
---|---|
Shares outstanding | 146.91m |
Free float | 145.78m |
P/E (TTM) | 32.57 |
Market cap | 31.08bn USD |
EPS (TTM) | 6.50 USD |
Annual div (ADY) | 1.92 USD |
---|---|
Annual div yield (ADY) | 0.90% |
Div ex-date | May 08 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 20 minutes, as of May 24 2024 01:41 BST.
More ▼